CYCC - Cyclacel Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Get access to 40+ years of historical data with Yahoo Finance Premium.Learn more
Currency in USD

Valuation Measures

Premium required to access annual data
Annual
Quarterly
Premium required to access monthly data
Monthly
Subscribe to Premium to download historical data
 
As of Date: 7/6/2020
Current
3/31/202012/31/20199/30/20196/30/2019
Market Cap (intraday) 5
22.02M6.63M11.52M6.82M9.30M
Enterprise Value 3
14.17M-4.06M-289.03k-7.11M-7.17M
Trailing P/E
N/AN/AN/AN/AN/A
Forward P/E 1
N/AN/AN/AN/AN/A
PEG Ratio (5 yr expected) 1
N/AN/AN/AN/AN/A
Price/Sales (ttm)
N/AN/A67.5236.5061.98
Price/Book (mrq)
2.120.570.830.430.53
Enterprise Value/Revenue 3
-9.01N/AN/AN/AN/A
Enterprise Value/EBITDA 6
-1.431.680.103.033.07

Trading Information

Stock Price History

Beta (5Y Monthly) 1.27
52-Week Change 3-62.46%
S&P500 52-Week Change 35.67%
52 Week High 319.6000
52 Week Low 33.8500
50-Day Moving Average 34.8159
200-Day Moving Average 38.7146

Share Statistics

Avg Vol (3 month) 3950.66k
Avg Vol (10 day) 3218.8k
Shares Outstanding 54.86M
Float 4.46M
% Held by Insiders 15.32%
% Held by Institutions 114.24%
Shares Short (Jun 14, 2020) 4220.36k
Short Ratio (Jun 14, 2020) 40.3
Short % of Float (Jun 14, 2020) 44.57%
Short % of Shares Outstanding (Jun 14, 2020) 44.53%
Shares Short (prior month May 14, 2020) 486.63k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Jul 31, 2016
Ex-Dividend Date 4N/A
Last Split Factor 21:20
Last Split Date 3Apr 14, 2020

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2019
Most Recent Quarter (mrq)Mar 30, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-35.88%
Return on Equity (ttm)-51.59%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-4.66M
EBITDA -9.88M
Net Income Avi to Common (ttm)-7.41M
Diluted EPS (ttm)-8.6090
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)8.92M
Total Cash Per Share (mrq)1.84
Total Debt (mrq)1.07M
Total Debt/Equity (mrq)10.33
Current Ratio (mrq)7.76
Book Value Per Share (mrq)12.08

Cash Flow Statement

Operating Cash Flow (ttm)-8.57M
Levered Free Cash Flow (ttm)-7.37M